Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: A 6-month retrospective study

Journal of Medical Economics

Volumn 13, Issue 4, 2010, Pages 599-609

  Yu, Andrew P ^a   Xie, Jipan ^a   Bensimon, Arielle ^a   Parikh, Kejal ^a   Wu, Eric Q ^a   Ben Hamadi, Rym ^a   Blum, Steven ^b   Haim Erder, M ^b  

^a ANALYSIS GROUP   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

citalopram; costs; escitalopram; generic entry; healthcare; SSRI; switching; utilization

Indexed keywords

CITALOPRAM; ESCITALOPRAM;

ADULT; ARTICLE; DATA BASE; DRUG COST; DRUG SUBSTITUTION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HEALTH; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; FEES, PHARMACEUTICAL; FEMALE; HEALTH SERVICES; HOSPITALIZATION; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 78650056749     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.521736     Document Type: Article

References (38)

1. The National Survey on Drug Use and Health Report: Depression among adults, November 2005 Available at: Http://www.oas.samhsa.gov/2k5/depression/ depression.pdf Accessed on October 1, 2009
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349: 1498-1504
3. Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 1997;54:989-91
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
5. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: How did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
6. Weilburg JB. An overview of SSRI and SNRI therapies for depression. Manag Care 2004;13:25-33
7. Panzarino Jr PJ, Nash DB. Cost-effective treatment of depression with selective serotonin reuptake inhibitors. Am J Manag Care 2001;7:173-184
8. Frank L, Revicki DA, Sorensen SV, et al. The economics of selective serotonin reuptake inhibitors in depression: A critical review. CNS Drugs 2001;15:59-83
9. Peveler R, Kendrick T, Buxton M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess 2005;9:1-134, iii
10. Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract 1998;47:446-52
11. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009:CD006532
12. Kasper S, Sacher J, Klein N, et al. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 2009;24:119-25
13. Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004;174:163-76
14. Guideline watch: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 2nd edn. Available at: Http://www.psychiatryonline. com/ pracGuide/pracGuideTopic-7.aspx. Accessed on October 1, 2009
15. Celexa package insert, available at http://www.frx.com/pi/celexa-pi.pdf. Accessed on October 1, 2009
16. Wu EQ, Greenberg PE, Yang E, et al. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: A comparison between escitalopram and other SSRI/SNRIs. J Med Econ 2009;12:124-35
17. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-36
18. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-17
19. Murdoch D, Keam SJ. Spotlight on escitalopram in the management of major depressive disorder. CNS Drugs 2006;20:167-70
20. Baldwin DS, Reines EH, Guiton C, et al. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007;41:1583-92
21. Baldwin DS. Escitalopram: Efficacy and tolerability in the treatment of depression. Hosp Med 2002;63:668-71
22. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002;7:40-4
23. Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: An extended analysis. Pharmacopsychiatry 2006;39:180-84
24. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149-55
25. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-37
26. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments metaanalysis. Lancet 2009;373:746-58
27. Fantino B, Moore N, Verdoux H, et al. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int Clin Psychopharmacol 2007;22:107-15
28. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005;21:631-42
29. Sørensen J, Stage KB, Damsbo N, et al. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry 2007;61:100-8
30. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-32
31. Greenberg PE. Does generic substitution always make sense? J Med Econ 2008;11:547-53
32. Blier P. Brand versus generic medications: The money, the patient and the research. J Psychiatry Neurosci 2003;28:167-8
33. Van Ameringen M, Mancini C, Patterson B, et al. Symptom relapse following switch from Celexa to generic citalopram: An anxiety disorders case series. J Psychopharmacol 2007;21:472-6
34. Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001;23:1720-3171
35. Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578-92
36. Lauzon V, Kaltenboek A, Yu AP, et al. The economic impact of generic switching for patients with major depressive disorder (MDD) treated with escitalopram or a patented SSRI. Presented at ISPOR 14th Annual International Meeting. Value Health 2009;12:A179
37. Panzer PE, Regan TS, Chiao E, et al. Implications of an SSRI generic step therapy pharmacy benefit design: An economic model in anxiety disorders. Am J Manag Care 2005;11:S370-9
38. McLaughlin TP, Eaddy MT, Grudzinski AN. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: Impact on depression-related treatment charges. Clin Ther 2004;26:115-24